Safety and efficacy of emicizumab and other novel agents in newborns and infants-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of emicizumab and other novel agents in newborns and infants

Published:2019-07-30 Issue:5 Volume:25 Page:
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Pierce Glenn F.¹,Hart Daniel P.¹²³,Kaczmarek Radoslaw¹⁴⁵^ORCID,

Affiliation:

1. Coagulation Products Safety Supply and Access Committee of the World Federation of Hemophilia Montreal Québec Canada

2. Barts and The London School of Medicine and Dentistry Blizard Institute, QMUL London UK

3. The Royal London Hospital Haemophilia Centre Barts Health NHS Trust London UK

4. Department of Pediatrics Indiana University School of Medicine Indianapolis IN USA

5. Laboratory of Glycobiology, Polish Academy of Sciences Hirszfeld Institute of Immunology and Experimental Therapy Wroclaw Poland

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.13822

Reference4 articles.

1. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors

2. Age dependency for coagulation parameters in paediatric populations

3. Developmental hemostasis: laboratory and clinical implications

4. Coagulation indices in very preterm infants from cord blood and postnatal samples

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B;Cochrane Database of Systematic Reviews;2024-02-27

2. Therapeutic and technological advancements in haemophilia care: Quantum leaps forward;Haemophilia;2022-05

3. Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives;Journal of Blood Medicine;2022-04

4. Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus;Journal of Clinical Medicine;2022-02-02

5. Real‐world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors;Haemophilia;2021-10-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3